SEC Comment Letter 0000000000-24-006522 to BioNexus Gene Lab Corp (BGLC)
BioNexus Gene Lab Corp
Date: June 6, 2024 · CIK: 0001737523 · Accession: 0000000000-24-006522
AI Filing Summary & Sentiment
File numbers found in text: 001-41750
Letter
United States securities and exchange commission logo June 6, 2024 Su-Leng Tan Lee Chief Executive Officer and Acting Chief Financial Officer BioNexus Gene Lab Corp Unit 02, Level 10, Tower B, Avenue 3, The Vertical Business Suite II, Bangsar South 8 Jalan Kerinchi Kuala Lumpur, Malaysia 59200 Re:BioNexus Gene Lab Corp Form 10-K filed April 16, 2024color:white;"_ File No. 001-41750 Dear Su-Leng Tan Lee: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Industrial Applications and Services
Show Raw Text
United States securities and exchange commission logo
June 6, 2024
Su-Leng Tan Lee
Chief Executive Officer and Acting Chief Financial Officer
BioNexus Gene Lab Corp
Unit 02, Level 10, Tower B, Avenue 3, The Vertical
Business Suite II, Bangsar South
8 Jalan Kerinchi
Kuala Lumpur, Malaysia 59200
Re:BioNexus Gene Lab Corp
Form 10-K filed April 16, 2024color:white;"_
File No. 001-41750
Dear Su-Leng Tan Lee:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services